Research programme: interleukin 1-beta converting enzyme inhibitors - Procter & Gamble
Alternative Names: Interleukin 1-beta converting enzyme inhibitors research programme - Procter & Gamble; PGE-3935199; PGE-527667Latest Information Update: 15 Sep 2005
Price :
$50 *
At a glance
- Originator Procter & Gamble
- Class
- Mechanism of Action Caspase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 15 Sep 2005 Discontinued - Preclinical for Inflammation in USA (PO)
- 09 Sep 2004 Preclinical trials in Inflammation in USA (PO)